Recruiting

Intra-operative Radiotherapy & External Beam Radiotherapy

Sponsor:

University College, London

Code:

NCT01792726

Conditions

Early Breast Cancer

Eligibility Criteria

Sex: Female

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Boost to the tumour bed

Study Details

Brief summary:

TARGIT-Boost is an international randomised clinical trial designed to test the hypothesis that the tumour bed boost delivered as a single dose of targeted intraoperative radiotherapy (TARGIT-B) is superior to the conventional course of external beam radiotherapy boost (EBRT-Boost), especially in women with high risk of local recurrence. It is a pragmatic trial in which each participating centre can use the local predefined inclusion/exclusion criteria for entry into the trial. Only centres with access to the Intrabeam® (Carl Zeiss) are eligible to enter patients into the trial.

Eligible patients are those with a higher risk of local recurrence after breast conserving surgery.

After giving consent patients are randomised to either TARGIT Boost or EBRT Boost. All patients will receive whole breast EBRT. They may receive any other adjuvant treatments as deemed necessary. The protocol recommends that patients be followed at six monthly intervals for three years and then annually.

The primary endpoint is ipsilateral breast recurrence rate. Secondary endpoints are relapse-free survival, site of recurrence, overall survival (breast-cancer specific and non-breast cancer deaths) patient satisfaction and quality of life.

Conditions

Early Breast Cancer

Study ID

NCT01792726

Start date

Jun, 2013

Status verified date

Jul, 2019

Completion date

Apr, 2022

Anticipated

Primary completion date

Jan, 2022

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria:

At least one of these criteria must be satisfied:

1. Less than 46 years of age
2. More than 45 years of age, but with one of the following poor prognostic factors:

1. lymphovascular invasion
2. gross nodal involvement (not micrometastasis)
3. more than one tumour in the breast but still suitable for breast conserving surgery through a single specimen
3. More than 45 years of age, but with at least two of the following poor prognostic factors

1. ER and/or PgR negative
2. Grade 3 histology
3. Positive margins at first excision
4. Those patients with large tumours which have responded to neo-adjuvant chemo- or hormone therapy in an attempt to shrink the tumour and are suitable for breast conserving surgery as a result.
5. Lobular carcinoma or Extensive Intraductal Component (EIC)
6. A list (one to many) of high risk factors are present (as predefined in the policy document) that give a high risk of local recurrence.
7. Patients with either HER2 positive or HER2 negative can be included.

Exclusion Criteria:

1. Bilateral breast cancer at the time of diagnosis.
2. Patients with any severe concomitant disease that may limit their life expectancy
3. Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years is 90% or greater (e.g., non-melanoma skin cancer, CIN, etc).
4. No more than 30 days can have elapsed between last breast cancer surgery (not axillary) and randomisation for patients in the post-pathology stratification unless part of a specific clinical trial that addresses the question of timing or tumour bed can be reliably identified, e.g., by ultrasound.

Study Design

Enrollment

1796 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: TARGIT

The experimental policy is to give targeted intra-operative radiotherapy (TARGIT-Boost) in a single dose to substitute for the usual boost dose, in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.

active comparator: External beam radiotherapy boost

The conventional policy is to receive radiation boost to the tumour bed delivered by external beam radiotherapy (EBRT) in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.

Interventions

Boost to the tumour bed

Boost to the tumour bed, with whole breast EBRT delivered according to local policy.

Primary outcome measure

  • Local tumour control (defined as no recurrent tumour in the ipsilateral breast). [ Time Frame: Five year median follow-up ]

Central Contacts and Locations

Locations

Helen Rey Breast Cancer Research Foundation

Recruiting

Los Angeles, California, United States

Contacts

Principal Investigator:

Dennis R Holmes, MD

Beaumont Health - Royal Oak

Recruiting

Detroit, Michigan, United States

Contacts

Principal Investigator:

Nayana Dekhne, MD

Lakeland Regional Health System

Recruiting

Saint Joseph, Michigan, United States

Contacts

Principal Investigator:

Benjamin T Gielda

Ashikari Breast Center

Recruiting

Dobbs Ferry, New York, United States, 10522

Cleveland Clinic

Recruiting

Cleveland, Ohio, United States

Contacts

Courtney Yanda

yandac@ccf.org

Principal Investigator:

Stephanie Valente

West Virginia University

Recruiting

Morgantown, West Virginia, United States

Contacts

Cortney Montgomery

comontgomery@hsc.wvu.edu

Principal Investigator:

Geraldine Jacobson

Aurora Breast Center

Recruiting

Green Bay, Wisconsin, United States

Contacts

Corinne Zipperer, RN

corinne.zipperer@aurora.org

Principal Investigator:

William Owens

More Information

Sponsor

University College, London

Last update posted

Jul 12, 2019

Last verified

Jul, 2019

Keywords

  • breast cancer
  • radiotherapy
  • TARGIT
  • Intrabeam

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University College, London on 2019-07-12.